A novel algorithm to differentiate between primary lung tumors and distant liver metastasis in lung cancers using an exosome based multi gene biomarker panel
- 1Division of Biological and Life Science, Ahmedabad University, Ahmedabad, Gujarat, India.
- 2Department of Life Science, School of Sciences, Gujarat University, Navrangpura, Ahmedabad, Gujarat, 380009, India. rakeshmrawal@gmail.com.
- 0Division of Biological and Life Science, Ahmedabad University, Ahmedabad, Gujarat, India.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A novel blood-based exosomal biomarker panel aids in early lung cancer liver metastasis detection and monitoring. This diagnostic tool improves patient prognosis through accurate risk assessment and survival prediction.
Area Of Science
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background
- Lung cancer liver metastasis (LCLM) significantly worsens patient prognosis due to a lack of early detection methods.
- Non-invasive diagnostic tools are crucial for timely intervention and improved outcomes in LCLM patients.
Purpose Of The Study
- To identify and validate circulating biomarkers for early diagnosis and monitoring of LCLM.
- To develop a predictive model using exosomal biomarkers for LCLM detection and prognosis.
Main Methods
- Validated an 8-gene panel in circulating tumor cells (CTC), cell-free RNA (cfRNA), and exosomes.
- Utilized multivariate analysis (PCA, ROC) to assess biomarker panel sensitivity and specificity.
- Validated a predictive model in a separate cohort and analyzed survival and immune infiltration correlations.
Main Results
- An 8-gene exosomal panel showed good discriminative value (AUC 0.7247).
- A refined 5-gene panel achieved high AUCs of 0.9488 (tissue) and 0.9924 (exosomes).
- A validated model with a risk score (RS > 0.2) predicted LCLM with 95% accuracy; four exosomal markers correlated with poor survival.
Conclusions
- A novel blood-based exosomal biomarker panel enables early diagnosis of LCLM.
- The panel facilitates monitoring of therapeutic response and prognostic evaluation in LCLM patients.
- This non-invasive approach holds promise for improving LCLM patient management.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

